gastric antral vascular ectasia-related bleeding in patients with livercirrhosis. Digestion 2009;79:143–50.

5. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): anupdate on clinical presentation, pathophysiology and treatment.Digestion 2008;77:131–7.

6. Kwan V, Bourke MJ, Williams SJ, Gillespie PE, Murray MA,Kaffes AJ, et al. Argon plasma coagulation in the management ofsymptomatic gastrointestinal vascular lesions: experience in 100consecutive patients with long-term follow-up. Am J Gastroenterol2006;101:58–63.

7. Pavey DA, Craig PI. Endoscopic therapy for upper-GI vascularectasias. Gastrointest Endosc 2004;59:233–8.

8. Chaves DM, Sakai P, Oliveira CV, Cheng S, Ishioka S.Watermelon stomach: clinical aspects and treatment with argonplasma coagulation. Arq Gastroenterol 2006;43:191–5.

9. Lecleire S, Ben-Soussan E, Antonietti M, Goria O, Riachi G,Lerebours E, et al. Bleeding gastric vascular ectasia treatedby argon plasma coagulation: a comparison between patientswith and without cirrhosis. Gastrointest Endosc 2008;67:219–25.

DOI 10.1002/art.30103Erratum

In the article by Kay et al in the April 2008 issue of Arthritis & Rheumatism (pages 964�975), there wereseveral errors in Tables 1 and 2, resulting from an unintentional systematic programming error pertaining toCRP units used in the DAS28-CRP calculations. In Table 1, the median (IQR) DAS28-CRP for patients in theplacebo plus MTX group, the golimumab (50 mg every 4 weeks) plus MTX group, the golimumab (50 mgevery 2 weeks) plus MTX group, the golimumab (100 mg every 4 weeks) plus MTX group, the golimumab (100mg every 2 weeks) plus MTX group, the golimumab (all regimens combined) plus MTX group, and the totalgroup, respectively, should have been reported as 5.8 (5.2, 6.4), 5.9 (5.5, 6.9), 5.4 (4.8, 6.7), 6.0 (5.1, 7.0), 5.7(4.8, 6.5), 5.8 (5.0, 6.6), and 5.8 (5.0, 6.6).

In Table 2, the mean � SD change from baseline in the DAS28 using CRP level in patients in the placebo plusMTX group, the golimumab (50 mg every 4 weeks) plus MTX group, the golimumab (50 mg every 2 weeks)plus MTX group, the golimumab (100 mg every 4 weeks) plus MTX group, the golimumab (100 mg every 2weeks) plus MTX group, and the golimumab (all regimens combined) plus MTX group, respectively, shouldhave been reported as �1.0 � 1.0, �2.0 � 1.3, �1.5 � 1.3, �2.0 � 1.5, �2.0 � 1.1, and �1.9 � 1.3. Themedian (IQR) change from baseline [P] in the DAS28 using CRP level should have been reported as �1.0(�1.8, �0.2), �2.0 (�2.6, �1.5) [0.003], �1.4 (�1.9, �0.7) [0.154], �2.3 (�3.5, 1.0) [0.005], �1.9 (�2.6, �1.2)[0.001], and �1.7 (�2.7, 1.0) [0.001], respectively. The number (%) of patients with a good responseaccording to the DAS28 using CRP level should have been reported as 2 (5.7), 7 (20.0), 9 (26.5), 11 (32.4),10 (29.4), and 37 (27.0), respectively. The number (%) of patients with a moderate response according to theDAS28 using CRP level should have been reported as 15 (42.9), 19 (54.3), 14 (41.2), 12 (35.3), 18 (52.9), and63 (46.0), respectively. The number (%) of patients with no response according to the DAS28 using CRP levelshould have been reported as 18 (51.4), 9 (25.7), 11 (32.4), 11 (32.4), 6 (17.6), and 37 (27.0), respectively. TheP value for the proportion of patients in the golimumab (50 mg every 4 weeks) plus MTX group, thegolimumab (50 mg every 2 weeks) plus MTX group, the golimumab (100 mg every 4 weeks) plus MTX group,the golimumab (100 mg every 2 weeks) plus MTX group, and the golimumab (all regimens combined) plusMTX group, respectively, who had good or moderate response according to the DAS28 using CRP levelshould have been reported as 0.027, 0.109, 0.109, 0.003, and 0.006. The number (%) of patients achievingremission according to the DAS28 using CRP level [P] in the placebo plus MTX group, the golimumab (50 mgevery 4 weeks) plus MTX group, the golimumab (50 mg every 2 weeks) plus MTX group, the golimumab (100mg every 4 weeks) plus MTX group, the golimumab (100 mg every 2 weeks) plus MTX group, and thegolimumab (all regimens combined) plus MTX group, respectively, should have been reported as 0 (0.0), 4(11.4) [0.039], 5 (14.7) [0.018], 5 (14.7) [0.018], 3 (8.8) [0.072], and 17 (12.4) [0.028].

We regret the errors.

3518 LETTERS